Mariner
CCCC icon

Mariner’s C4 Therapeutics CCCC Stock Holding History

Mariner’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$334K Sell
127,517
-533
-0.4% -$1.25K ﹤0.01% 2772
2025
Q4 		$245K Sell
128,050
-187
-0.1% -$443 ﹤0.01% 3018
2025
Q3 		$285K Sell
128,237
-4,528
-3% -$10.9K ﹤0.01% 2859
2025
Q2 		$190K Sell
132,765
-47,607
-26% -$69.2K ﹤0.01% 3069
2025
Q1 		$289K Buy
180,372
+12,397
+7% +$37K ﹤0.01% 2657
2024
Q4 		$605K Buy
167,975
+37,564
+29% +$187K ﹤0.01% 2028
2024
Q3 		$743K Buy
130,411
+2,532
+2% +$15.2K ﹤0.01% 1832
2024
Q2 		$591K Sell
127,879
-158
-0.1% -$942 ﹤0.01% 1926
2024
Q1 		$1.05M Hold
128,037
– – ﹤0.01% 1469
2023
Q4 		$723K Buy
128,037
+1,546
+1% +$3.52K ﹤0.01% 1674
2023
Q3 		$235K Sell
126,491
-15,317
-11% -$46.7K ﹤0.01% 2377
2023
Q2 		$390K Buy
141,808
+13,814
+11% +$44.4K ﹤0.01% 1922
2023
Q1 		$402K Sell
127,994
-93
-0.1% -$548 ﹤0.01% 1833
2022
Q4 		$756K Buy
128,087
+2,683
+2% +$22.2K ﹤0.01% 1381
2022
Q3 		$1.1M Sell
125,404
-175
-0.1% -$1.82K ﹤0.01% 1007
2022
Q2 		$947K Buy
125,579
+549
+0.4% +$4.83K ﹤0.01% 916
2022
Q1 		$3.03M Buy
+125,030
New +$3.04M 0.01% 615

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mariner's CCCC Position: Q1 2026 in Review

Mariner reduced its C4 Therapeutics (CCCC) stake by 0.42% in Q1 2026, selling an estimated $1.25K and leaving 127,517 shares worth $334K. The position accounts for ﹤0.01% of the portfolio, ranked #2772.

Mariner first reported a position in CCCC in Q1 2022 and has held it in 17 quarters since. The position peaked at $3.03M in Q1 2022. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Mariner held 127,517 shares of C4 Therapeutics worth $334K as of Q1 2026.
  • Mariner sold 533 C4 Therapeutics shares in Q1 2026, an estimated $1.25K.
  • C4 Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2772 holding.
  • Mariner first reported a position in C4 Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Mariner's C4 Therapeutics position peaked at $3.03M in Q1 2022.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.